Commercial Launch PreparationMIST has maintained its launch infrastructure and has already hired regional and district sales managers in preparation for the etripamil launch.
Financial StabilityMIST is expected to receive $75M in net proceeds upon approval from their RTW deal, which combined with proceeds from a recent financing, extends the cash runway into the first half of 2027.
Regulatory ApprovalThe FDA did not raise any concerns regarding the clinical package of the etripamil NDA, which is a positive indicator for approval.